SciBase receives initial order for clinical study from Castle Biosciences

Following the signing of the collaboration agreement, Castle has also invested in SciBase and is now SciBase second largest shareholder.  Following the signing of the collaboration agreement, Castle has also invested in SciBase and is now SciBase second largest shareholder.  "The collaboration with Castle Biosciences is moving forward at a fast pace and this first order signals the initiation of our first joint study,"  said Pia Renaudin , CEO of SciBase.  "At SciBase we are very excited...

STOCKHOLM, 23/09/2025 (informazione.news - comunicati stampa - salute e benessere)

Following the signing of the collaboration agreement, Castle has also invested in SciBase and is now SciBase second largest shareholder. 

 said  , CEO of SciBase. 

Pia Renaudin , CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

 DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: certifiedadviser@carnegie.se

 

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-receives-initial-order-for-clinical-study-from-castle-biosciences,c4238283

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/scibase-receives-initial-order-for-clinical-study-from-castle-biosciences-302564012.html